New version of SOPHiA Whole Exome Solution to accelerate rare disease characterization SOPHiA GENETICS, a leader in Data-Driven Medicine, has announced at the American Society of Human Genetics Annual Meeting (ASHG) the release of the new version of its SOPHiA Whole Exome Solution. This advanced genomic application is reducing the…..
$50 million in first close of new advanced therapies fund 4BIO Capital, an international venture capital firm focused solely on the advanced therapies sector, has completed the first close of its second venture fund, 4BIO Ventures II. Over $50 million of capital has been committed from family offices and institutional…..
FEATURE STORY ● The landscape of early clinical gene therapies outside oncology BASIC SCIENCE ● Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL CLINICAL TRIALS/DATA ● ATL1102 for DMD commencement of European regulatory interactions ● UniQure stays a step ahead in hemophilia B FINANCIAL DATA ● Passage Bio Closes $110…..